Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the
cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases …

Clinical presentations of atherothrombotic vascular disease, such as acute coronary
syndromes, ischemic stroke or transient ischemic attack, and symptomatic peripheral arterial …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …

Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …

The most common cause of morbidity and mortality in developed countries results from
atherosclerosis and superimposed thrombosis (atherothrombosis) leading to partial or …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …

Platelets are now regarded as playing a dominant role in cardiovascular medicine since our
recent understanding of acute coronary syndrome as an atherothrombotic process. This …

Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic
events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT …

Antiplatelet drugs are important components in the management of atherothrombotic
vascular disease. However, several limitations restrict the safety and efficacy of current …